High-throughput screen to identify modulators of CendR-mediated cellular uptake
高通量筛选以鉴定 CendR 介导的细胞摄取调节剂
基本信息
- 批准号:8262597
- 负责人:
- 金额:$ 4.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-02-01 至 2014-01-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAmino AcidsAntineoplastic AgentsArginineBindingBinding SitesBiochemicalBiologicalBiological AssayC-terminalCell LineCell Surface ReceptorsCell surfaceCellsChemicalsChemotherapy-Oncologic ProcedureCollaborationsCoupledDevelopmentDoseElementsFluorescence PolarizationGenomicsHomingIn VitroInfectious AgentInflammatoryLeadLibrariesLysineMediatingMolecularMolecular WeightMorphologic artifactsNamesNeuropilin-1NeuropilinsPathway interactionsPenetrationPeptidesPositioning AttributeProteinsProteolytic ProcessingSystemTissue SampleTissuesToxinTumor TissueValidationVenomsWorkbasecarboxyl grouphigh throughput screeninginnovationnanoparticlenovelnovel diagnosticsnovel therapeuticssmall moleculesmall molecule librariestooltumoruptake
项目摘要
DESCRIPTION (provided by applicant): This application proposes high-throughput screening for small molecular weight compounds that mimic the internalizing and tissue-penetrating peptide motif R/KXXR/K (R=arginine; K=lysine; X=any amino acid). Peptides and proteins containing this motif activate a pinocytotic transport pathway into cells and through tissues by binding to a cell surface receptor, neuropilin-1. The R/KXXR/K motif has to be in a C-terminal position to bind to neuropilin; even blocking the C-terminal carboxyl group of the arginine residue eliminates the activity. Because of this feature, the motif has been designated the C-end Rule or CendR motif. Tumor- specific homing peptides that are internalized into cells and spread within tumor tissue contain both a specific tumor-homing sequence and a cryptic CendR motif, which is activated in tumors by proteolytic processing. A payload can either be covalently coupled to a CendR peptide or simply co-administered with it to achieve tissue penetration. Thus, the CendR pathway provides a way of overcoming one of the main limitations of cancer chemotherapy, poor penetration of anticancer drugs into tumor tissue. This pathway can also transport nanoparticles, enabling deep tissue delivery of nanoparticle payloads. Many inflammatory proteins, infectious agents and venoms possess proteins with CendR elements that may mediate entry into cells and spreading through tissues. Novel high-throughput assays that are based on the binding of a CendR peptide to a fragment of neuropilin-1 have been developed in collaboration with the Sanford-Burnham Center for Chemical Genomics, and a pilot screen using the assay has been successfully carried out. Larger screens are now proposed to assemble a panel of "hits". These molecules will be validated as specific modulators of the CendR pathway and their biological activity as agonists or antagonists of the CendR pathway will be determined assessed. The compounds resulting from this work that resemble the CendR peptides in their activity will be useful tools for introducing materials into cells and tissues, as well as for exploring the molecular basis of the CendR tissue penetration phenomenon. They may also serve as lead compounds in the development of novel diagnostic and therapeutic delivery systems. The screens may also yield antagonists of the CendR system, which could be useful in inhibiting the transport of toxins and infectious agents through the CendR transport system.
描述(由申请人提供):本申请提出高通量筛选小分子量化合物,模拟内化和组织穿透肽基序R/KXXR/K (R=精氨酸;K=赖氨酸;X=任何氨基酸)。含有该基序的肽和蛋白质通过与细胞表面受体neuropilin-1结合,激活进入细胞并通过组织的胞质转运途径。R/KXXR/K基序必须位于c端才能与neuropilin结合;即使阻断精氨酸残基的c端羧基也能消除活性。由于这一特点,该基序被称为c端规则或CendR基序。肿瘤特异性归巢肽被内化到细胞中并在肿瘤组织中传播,它包含一个特定的肿瘤归巢序列和一个隐式的CendR基序,它在肿瘤中通过蛋白水解过程被激活。有效载荷既可以与CendR肽共价偶联,也可以简单地与它共同施用以实现组织渗透。因此,CendR途径提供了一种克服癌症化疗的主要限制之一的方法,即抗癌药物难以渗透到肿瘤组织中。这种途径也可以运输纳米颗粒,使纳米颗粒有效载荷能够在组织深处传递。许多炎症蛋白、感染因子和毒液都含有含有CendR元素的蛋白,这些蛋白可能介导进入细胞并在组织中扩散。与斯坦福-伯纳姆化学基因组学中心合作开发了基于CendR肽与neuropilin-1片段结合的新型高通量检测方法,并成功地进行了使用该检测方法的试点筛选。现在,更大的屏幕被提议组装一个“热门”面板。这些分子将被验证为CendR通路的特异性调节剂,它们作为CendR通路的激动剂或拮抗剂的生物活性将被确定评估。从这项工作中得到的与CendR肽活性相似的化合物将成为将材料引入细胞和组织以及探索CendR组织渗透现象的分子基础的有用工具。它们也可以作为先导化合物用于开发新的诊断和治疗递送系统。筛选也可能产生CendR系统的拮抗剂,这可能有助于抑制毒素和感染因子通过CendR运输系统的运输。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERKKI RUOSLAHTI其他文献
ERKKI RUOSLAHTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERKKI RUOSLAHTI', 18)}}的其他基金
High-throughput screen to identify modulators of CendR-mediated cellular uptake
高通量筛选以鉴定 CendR 介导的细胞摄取调节剂
- 批准号:
8416337 - 财政年份:2012
- 资助金额:
$ 4.88万 - 项目类别:
Injury-targeted decorin for systemic anti-fibrotic treatment
用于全身抗纤维化治疗的损伤靶向核心蛋白聚糖
- 批准号:
8199150 - 财政年份:2011
- 资助金额:
$ 4.88万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 4.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 4.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 4.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)